通过增加DNA损伤和G2细胞周期停止废止,ATR抑制使细胞具有放射性敏感性
Scott J Bright1, Mandira Manandhar1, David B Flint1
1Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
JCI insight
|September 5, 2024
概括
将ATR抑制与放射治疗 (包括光子和质子束) 结合起来,通过导致持续的DNA损伤和改善瘤生长延迟来增强癌症治疗. 这种方法也增加了瘤微环境中的巨细胞透.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 分子生物学分子生物学
背景情况:
- ATAXIA telangiectasia和Rad3相关蛋白 (ATR) 对于DNA损伤反应和细胞周期调节至关重要.
- 癌细胞往往改变了DNA损伤反应,使它们易受放射敏感化策略的影响.
- 在DNA修复和细胞循环检查点中ATR的作用突显了它作为放射治疗中的治疗点的潜力.
研究的目的:
- 评估ATR抑制剂AZD6738在各种癌症细胞系中的放射敏感化潜力.
- 研究将AZD6738与光子和质子辐射疗法结合的效果.
- 评估这种联合治疗对瘤生长,存活率和瘤微环境的影响.
主要方法:
- 用AZD6738和光子/质子辐射疗法治疗各种癌症细胞系.
- 对DNA损伤,细胞循环停止 (G2) 和微核形成的评估.
- 使用乳腺癌模型进行体内研究,以评估瘤生长延迟和生存率.
- 分析瘤微环境中的免疫细胞透,特别是巨细胞.
主要成果:
- AZD6738有效地使癌细胞对光子和质子辐射疗法的敏感.
- 放射性敏感性是由持续的DNA损伤和G2细胞周期停止的废除所介导的.
- 组合疗法导致放射治疗后微核形成增加.
- 在乳腺癌模型中,AZD6738和辐射的结合显著延迟了瘤生长和延长了生存时间.
- 在用AZD6738和放射治疗治疗的瘤中观察到巨细胞透的增加.
结论:
- 用AZD6738药理抑制ATR是一种有前途的策略,用于各种癌症类型的放射敏感化.
- 将ATR抑制与放射治疗结合起来,可以通过DNA损伤和细胞循环中断来增强抗瘤效应.
- 组合疗法通过增加巨细胞透来调节瘤微环境,这表明免疫疗法组合的潜力.
- 需要对ATR抑制剂与放射治疗进行进一步的临床研究.
更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.0K
05:39Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
Published on: April 5, 2024
781
相关概念视频
DNA Damage can Stall the Cell Cycle
9.1K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.1K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Negative Regulator Molecules
35.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
DNA Damage Can Stall the Cell Cycle
2.6K
2.6K
Mutations
35.2K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
35.2K
